Intended for healthcare professionals

News

Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval

BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n326 (Published 03 February 2021) Cite this as: BMJ 2021;372:n326

Read our latest coverage of the coronavirus outbreak

  1. Jacqui Wise
  1. London, UK

The UK’s approach of leaving an interval of three months between doses of the Oxford AstraZeneca covid-19 vaccine has been supported by new data, with the Oxford University researchers also saying the vaccine “may have a substantial impact on transmission.”

The paper, a preprint currently under review at the Lancet, is an analysis of additional data from trials involving 17 177 participants in the UK, Brazil, and South Africa.1 It includes the results of a further month of data collection with 332 cases of symptomatic covid-19—an additional 201 cases than were previously reported.2

A single standard dose of vaccine provided 76% protection overall against symptomatic covid-19 in the first 90 days after vaccination with protection not falling in this time frame. It is not clear, however, how long protection might last with a single …

View Full Text